Home » Topics » BioWorld Science

BioWorld Science
RSS

Safety monitoring committee recommends continuation of phase IIb study of RV-001 in prostate cancer

July 12, 2021

FDA clears initiation of phase II trial of pyrilutamide in androgenetic alopecia

July 12, 2021

Dosing begins in phase I study in China of IBI-323 for advanced malignant tumors

July 12, 2021

Rare coding variant increases risk of Y chromosome loss, diabetes

July 12, 2021

Ranitidine bismuth citrate shows potency for treating SARS-CoV-2 infection

July 12, 2021

ViiV initiates phase II study of GSK-3810109A in antiretroviral-naive HIV-1-infected adults

July 12, 2021

Enrollment ongoing first-in-human study of PBI-200

July 12, 2021

Eli Lilly initiates phase I study of LY-3819469

July 12, 2021

FDA places clinical hold on phase I/II study of SIG-001 in hemophilia A

July 12, 2021

Phase Ib extension data for belapectin plus Keytruda in melanoma and head and neck cancer

July 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy
BioWorld
Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights,...